Qun-sheng YUAN, Xue-mei LI. Updates and Interpretation on 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 213-218. doi: 10.3969/j.issn.1674-9081.2018.03.005
Citation: Qun-sheng YUAN, Xue-mei LI. Updates and Interpretation on 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 213-218. doi: 10.3969/j.issn.1674-9081.2018.03.005

Updates and Interpretation on 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder

doi: 10.3969/j.issn.1674-9081.2018.03.005
More Information
  • Corresponding author: LI Xue-mei Tel:010-69154056, E-mail: lixmpumch@126.com
  • Received Date: 2017-11-08
  • Publish Date: 2018-05-30
  • The Kidney Disease:Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) was originally published in 2009, which assists practitioners in clinical diagnosis, prevention, and treatment of CKD-MBD. However, the Guideline Work Group acknowledged the lack of sufficient evidence for the base of recommendations. The Guideline included specific research recommendations to encourage investigators to help fill the gaps and bolster the evidence base. With the accumulation of related results of multiple randomized and controlled trials and prospective cohort studies since 2009, 2017 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update on the prior guideline published in 2009. Specifically, the topic areas for which updated recommendations are issued include the diagnosis of bone abnormalities in CKD-MBD, treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance, treatment of parathyroid hormone abnormalities in CKD-MBD, and so on. A total of 12 recommendations were reevaluated and updated based on new data. This report interprets the updates on 2017 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD and describes the results of these proceedings, which highlights the significance of KDIGO CKD-MBD guideline in clinical practice.
  • loading
  • [1] Kidney disease:improving global outcomes (KDIGO) CKD-MBD work group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2009, 76:S1-S130. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM19644521
    [2] Kidney disease:improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2017, 7:1-59. doi:  10.1016/j.kisu.2017.04.001
    [3] Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease[J]. Kidney Int, 2000, 58:396-399. doi:  10.1046/j.1523-1755.2000.00178.x
    [4] Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States[J]. J Am Soc Nephrol, 2006, 17:3223-3232. doi:  10.1681/ASN.2005111194
    [5] Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population[J]. Am J Kidney Dis, 2004, 44:672-679. doi:  10.1016/S0272-6386(04)00958-8
    [6] Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients[J]. Kidney Int, 2014, 85:166-173. doi:  10.1038/ki.2013.279
    [7] Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bonemineral density and biochemical markers of bone turnover inpredicting fracture in CKD stage 5D patients-a single-centercohort study[J]. Nephrol Dial Transplant, 2012, 27:345-351. doi:  10.1093/ndt/gfr317
    [8] West SL, Lok CE, Langsetmo L, et al. Bone mineral density predictsfractures in chronic kidney disease[J]. J Bone Miner Res, 2015, 30:913-919. doi:  10.1002/jbmr.2406
    [9] Haghverdi F, Mortaji S, Soltani P, et al. Effect of raloxifene onparathyroid hormone in osteopenic and osteoporoticpostmenopausal women with chronic kidney disease stage 5[J]. Iran J Kidney Dis, 2014, 8:461-466. http://europepmc.org/abstract/med/25362221
    [10] Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects ofdenosumab on fracture and bone mineral density by level of kidneyfunction[J]. J Bone Miner Res, 2011, 26:1829-1835. doi:  10.1002/jbmr.403
    [11] EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis[J]. N Engl J Med, 2012, 367:2482-2494. doi:  10.1056/NEJMoa1205624
    [12] Block GA, Kilpatrick RD, Lowe KA, et al. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization inpatients on hemodialysis[J]. Clin J Am Soc Nephrol, 2013, 8:2132-2140. doi:  10.2215/CJN.04260413
    [13] Chartsrisak K, Vipattawat K, Assanatham M, et al. Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients[J]. BMC Nephrol, 2013, 14:14-20. doi:  10.1186/1471-2369-14-14
    [14] Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality inpatients with chronic kidney disease[J]. Clin J Am Soc Nephrol, 2010, 5:2251-2257. doi:  10.2215/CJN.00810110
    [15] Fouque D, Roth H, Pelletier S, et al. Control of mineral metabolism and bone disease in haemodialysis patients:which optimal targets?[J]. Nephrol Dial Transplant, 2013, 28:360-367. doi:  10.1093/ndt/gfs404
    [16] Gross P, Six I, Kamel S, et al. Vascular toxicity of phosphate in chronic kidney disease:beyond vascular calcification[J]. Circ J, 2014, 78:2339-2346. doi:  10.1253/circj.CJ-14-0735
    [17] Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease[J]. Kidney Int, 2013, 83:959-966. doi:  10.1038/ki.2012.403
    [18] Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD[J]. J Am Soc Nephrol, 2012, 23:1407-1415. doi:  10.1681/ASN.2012030223
    [19] Di Iorio B, Bellasi A, Russo D, et al. Mortality in kidney disease patients treated with phosphate binders:a randomized study[J]. Clin J Am Soc Nephrol, 2012, 7:487-493. doi:  10.2215/CJN.03820411
    [20] Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients:results of an openlabel 24-month randomized clinical trial[J]. Am J Kidney Dis, 2013, 62:771-778. doi:  10.1053/j.ajkd.2013.03.023
    [21] Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality inpatients with chronic kidney disease:an updated systematic reviewand meta-analysis[J]. Lancet, 2013, 382:1268-1277. doi:  10.1016/S0140-6736(13)60897-1
    [22] Karavetian M, de Vries N, Elzein H, et al. Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients, Lebanon[J]. Patient Educ Couns, 2015, 98:1116-1122. doi:  10.1016/j.pec.2015.05.005
    [23] Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population[J]. Nephrol Dial Transplant, 2011, 26:1948-1955. doi:  10.1093/ndt/gfq219
    [24] Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets[J]. Kidney Int, 2012, 81:1116-1122. doi:  10.1038/ki.2011.490
    [25] St Peter WL, Li Q, Liu J, et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006[J]. Clin J Am Soc Nephrol, 2009, 4:354-360. doi:  10.2215/CJN.05241008
    [26] Denburg MR, Tsampalieros AK, de Boer IH, et al. Mineral metabolism and cortical volumetric bone mineral density inchildhood chronic kidney disease[J]. J Clin Endocrinol Metab, 2013, 98:1930-1938. doi:  10.1210/jc.2012-4188
    [27] Ok E, Asci G, Bayraktaroglu S, et al. Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis[J]. J Am Soc Nephrol, 2016, 27:2475-2486. doi:  10.1681/ASN.2015030268
    [28] Spasovski G, Gelev S, Masin-Spasovska J, et al. Improve-ment of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium[J]. Bone, 2007, 41:698-703. doi:  10.1016/j.bone.2007.06.014
    [29] Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease:the PRIMO randomized controlled trial[J]. JAMA, 2012, 307:674-684. doi:  10.1001/jama.2012.120
    [30] Li XH, Feng L, Yang ZH, et al. The effect of active vitamin d on cardiovascular outcomes in predialysis chronic kidney diseases:a systematic review and meta-analysis[J]. Nephrology (Carlton), 2015, 20:706-714. doi:  10.1111/nep.12505
    [31] Parfey PS, Drüeke TB, Block GA, et al. The effects of cinacalcet in older and younger patients on hemodialysis:the Evaluation of Cinacalcet HCI Therapy to Lower Cardiovascular Events (EVOLVE) trial[J]. Clin J Am Soc Nephrol, 2015, 10:791-799. doi:  10.2215/CJN.07730814
    [32] Parfrey PS, Chertow GM, Block GA, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet:the EVOLVE trial[J]. J Clin Endocrinol Metab, 2013, 98:4834-4844. doi:  10.1210/jc.2013-2975
    [33] Behets GJ, Spasovski G, Sterling LR, et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism[J]. Kidney Int, 2015, 87:846-856. doi:  10.1038/ki.2014.349
    [34] Raggi P, Chertow GM, Torres PU, et al. The advance study:a randomized study to evaluate the effects of cinacalcet plus low-dosevitamin D on vascular calcification in patients on hemodialysis[J].Nephrol Dial Transplant, 2011, 26:1327-1339. doi:  10.1093/ndt/gfq725
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (366) PDF downloads(975) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return